Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 2/2019

01-04-2019 | Editorial

Should positron emission tomography be the standard of care for non-invasive surveillance following cardiac transplantation?

Authors: Robert J. H. Miller, MD, Jon A. Kobashigawa, MD, Daniel S. Berman, MD, FACC

Published in: Journal of Nuclear Cardiology | Issue 2/2019

Login to get access

Excerpt

The number of patients with end-stage heart failure has increased over the last decade and is expected to continue to rise. Cardiac transplant is the only established, cost-effective therapy for end-stage heart failure.1 Median survival following cardiac transplant is now greater than 13 years, and as a result many patients are now surviving until they develop cardiac allograft vasculopathy (CAV).2 In patients who survive at least 5 years after transplant, CAV accounts for over a third of deaths, many of which occur suddenly.3 CAV is also the most common indication for re-transplantation in patients who survive at least one year.4 …
Appendix
Available only for authorised users
Literature
1.
Kilic A, Phillips G, Chimanji N, Sai-Sudhakar CB, Hasan A, Higgins RSD, et al. Cost comparison between heart transplantation and left ventricular assist device implantation. J Cardiac Fail. 2014;20:S84.CrossRef
2.
Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al. The registry of the international society for heart and lung transplantation: thirty-fourth adult heart transplantation report—2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36:1037-46.CrossRefPubMed
3.
Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report—2009. J Heart Lung Transplant. 2009;28:1007-22.CrossRefPubMed
4.
Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation. J Heart Lung Transplant. 2014;33:996-1008.CrossRefPubMed
5.
Pollack A, Nazif T, Mancini D, Weisz G. Detection and imaging of cardiac allograft vasculopathy. JACC Cardiovasc Imaging. 2013;6:613-23.CrossRefPubMed
6.
Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717-27.CrossRefPubMed
7.
Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant. 1995;14:632-9.PubMed
8.
Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.CrossRefPubMed
9.
Thompson D, Koster MJ, Wagner RH, Heroux A, Barron JT. Single photon emission computed tomography myocardial perfusion imaging to detect cardiac allograft vasculopathy. Eur Heart J Cardiovasc Imaging. 2012;13:271-75.CrossRefPubMed
10.
Chirakarnjanakorn S, Starling RC, Popovic ZB, Griffin BP, Desai MY. Dobutamine stress echocardiography during follow-up surveillance in heart transplant patients: diagnostic accuracy and predictors of outcomes. J Heart Lung Transplant. 2015;34:710-7.CrossRefPubMed
11.
Wever-Pinzon O, Romero J, Kelesidis I, Wever-Pinzon J, Manrique C, Budge D, et al. Coronary computed tomography angiography for the detection of cardiac allograft vasculopathy: a meta-analysis of prospective trials. J Am Coll Cardiol. 2014;63:1992-2004.CrossRefPubMed
12.
Chih S, Chong AY, Erthal F, deKemp RA, Davies RA, Stadnick E, et al. PET assessment of epicardial intimal disease and microvascular dysfunction in cardiac allograft vasculopathy. J Am Coll Cardiol. 2018;71:1444-56.CrossRefPubMed
13.
Wu Y-W, Chen Y-H, Wang S-S, Jui H-Y, Yen R-F, Tzen K-Y, et al. PET assessment of myocardial perfusion reserve inversely correlates with intravascular ultrasound findings in angiographically normal cardiac transplant recipients. J Nucl Med. 2010;51:906-12.CrossRef
14.
Allen-Auerbach M, Schöder H, Johnson J, Kofoed K, Einhorn K, Phelps ME, et al. Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. J Heart Lung Transplant. 1999;18:211-9.CrossRef
15.
Mc Ardle BA, Davies RA, Chen L, Small GR, Ruddy TD, Dwivedi G, et al. Prognostic value of rubidium-82 positron emission tomography in patients after heart transplant. Circulation. 2014;7:930-7.PubMed
16.
Konerman MC, Lazarus JJ, Weinberg RL, Shah RV, Ghannam M, Hummel SL, et al. Reduced myocardial flow reserve by positron emission tomography predicts cardiovascular events after cardiac transplantation. Circ Heart Fail. 2018;11:e004473.CrossRefPubMedPubMedCentral
17.
Bravo PE, Bergmark BA, Vita T, Taqueti VR, Gupta A, Seidelmann S, et al. Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. Eur Heart J. 2018;39:316-23.CrossRefPubMed
18.
19.
Chan SY, Kobashigawa J, Stevenson LW, Brownfield E, Brunken RC, Schelbert HR. Myocardial blood flow at rest and during pharmacological vasodilation in cardiac transplants during and after successful treatment of rejection. Circulation. 1994;90:204-12.CrossRef
20.
Metadata
Title
Should positron emission tomography be the standard of care for non-invasive surveillance following cardiac transplantation?
Authors
Robert J. H. Miller, MD
Jon A. Kobashigawa, MD
Daniel S. Berman, MD, FACC
Publication date
01-04-2019
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 2/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-01508-8

Other articles of this Issue 2/2019

Journal of Nuclear Cardiology 2/2019 Go to the issue

Editorial

Failure to accurately identify the number of diseased coronary arteries: A weakness of SPECT MPI

Images that Teach

Stress for a stressed out heart: Classic cardiac PET findings in takotsubo cardiomyopathy

Original Article

Corrected coronary opacification decrease from coronary computed tomography angiography: Validation with quantitative 13N-ammonia positron emission tomography

Editorial

Ischemia and inflammation on chronic kidney disease

Editorial

Dedicated cardiac CZT SPECT is steadily moving to achieve its destiny

Original Article

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits